Enhanced Training and Mentorship of Hematologic Oncologists

加强血液肿瘤学家的培训和指导

• 批准号: 9491246
• 负责人: Lillian Sung
• 金额: $ 30.62万
• 依托单位: AMERICAN SOCIETY OF HEMATOLOGY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-12 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9491246
• 关键词: American Society of Hematology; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Development; Diagnosis; Disease; Dysmyelopoietic Syndromes; Education; Educational Curriculum; Educational process of instructing; Educational workshop; Ensure; Evaluation; Evolution; Exposure to; Faculty; Fellowship; Fostering; Foundations; Future; Goals; Grant; Health; Hematologic Neoplasms; Hematological Disease; Hematologist; Hematology; Home environment; Hour; Institutes; Institution; Knowledge; Laboratories; Late Effects; Lead; Malignant - descriptor; Malignant Neoplasms; Mentors; Mentorship; Methodology; Methods; Multiple Myeloma; Myeloproliferative disease; Oncologist; Online Systems; Outcome; Patient Outcomes Assessments; Patient-Focused Outcomes; Patients; Quality of life; Research; Research Methodology; Research Personnel; Research Training; Resources; Risk stratification; Scholarship; Scientist; Supportive care; Time; Training; Training and Education; Translating; United States; Work; anticancer research; cancer diagnosis; career; career development; clinical care; cost effective; cost effectiveness; design; experience; improved; improved outcome; innovation; knowledge base; leukemia/lymphoma; molecular targeted therapies; novel therapeutics; online resource; patient engagement; patient oriented; patient oriented research; peer networks; precision medicine; program dissemination; programs; recruit; responsible research conduct; skills; success; survivorship

Project Summary Hematologic malignancies are a major health problem. There are approximately 1.2 million people in the United States living with leukemia, lymphoma, or myeloma, and these malignancies accounted for 10% of all new cancer diagnoses in 2016.1 Fortunately, the field of has experienced robust and promising advances in recent years. However, many patients with hematological malignancies continue to have unacceptable outcomes,8-10 and much work remains to improve their survival. Furthermore, patient-reported outcomes and cost-effectiveness are becoming key issues that are relevant to patients. In an effort to further advance the field of hematological malignancy and to improve patient outcomes, the American Society of Hematology (ASH) created the Clinical Research Training Institute (CRTI) 14 years ago to train junior researchers in the conduct of patient-oriented research and provide them the networks and mentorship to succeed in these careers. CRTI is a year-long program that annually exposes 20 fellows (applicants who at the time of their application and for the duration of the CRTI program are in hematology-related fellowship training) and junior faculty (applicants have completed their fellowship training within the past three years) to foundation, methodologies, and application of patient-oriented clinical research. Each fellow receives (1) extensive education in clinical research methods; (2) one-on-one exposure to leaders in the field of cancer research; (3) the opportunity for junior investigators to form peer networks; and (4) formal mentorship from successful clinical researchers. The Institute consists of a week-long Summer Workshop that includes interactive didactic presentations, small group discussions, training in the responsible conduct of research, and numerous hours of one-on-one and ad hoc group discussions. The Summer Workshop (in August) is followed by the December Class and the Final Class (in May) during which the entire class convenes to discuss their progress and obstacles. Each trainee identifies a CRTI mentor with whom he or she works during the entire program year to ensure career and research progress. Under this grant, we intend to expand the training curriculum to incorporate innovative teaching strategies, introduce new sessions consistent with current priorities such as patient engagement and precision medicine, enhance dissemination of the program through on-line resources, and increase connections via web- based approaches.

项目摘要 血液恶性肿瘤是一个主要的健康问题。美国大约有120万人 患有白血病、淋巴瘤或骨髓瘤的州占所有新发癌症的10% 2016.1幸运的是，近年来，该领域取得了强劲而有希望的进展。 然而，许多恶性血液病患者的结局仍然不可接受，8-10例， 仍有许多工作要做，以改善他们的生存状况。此外，患者报告的结果和成本效益 正在成为与患者相关的关键问题。 为了进一步推进血液恶性肿瘤领域并改善患者结局， 美国血液学会（ASH）14年前创建了临床研究培训学院（CRTI）， 培训初级研究人员进行以病人为导向的研究，并为他们提供网络， 在这些职业生涯中取得成功。 CRTI是一个为期一年的计划，每年暴露20名研究员（申请人在申请时 在CRTI项目期间，他们参加了血液学相关的奖学金培训）和初级教师培训。 （申请人在过去三年内完成了研究金培训），以基金会，方法， 以病人为中心的临床研究的应用。每个研究员接受（1）广泛的临床教育 研究方法;（2）一对一接触癌症研究领域的领导者;（3） 初级研究人员形成同行网络;（4）成功的临床研究人员的正式指导。的 研究所包括为期一周的暑期工作坊，包括互动教学演示，小组 讨论，负责任地进行研究的培训，以及无数小时的一对一和临时的 小组讨论。夏季研讨会（8月）之后是12月班和最后一班 (in五月），在此期间，整个班级召开会议，讨论他们的进展和障碍。每个学员都要确定 一个CRTI导师与他或她在整个计划年，以确保职业和研究工作 中求进工作总在这笔拨款下，我们打算扩大培训课程， 战略，引入与当前优先事项（如患者参与和精确度）一致的新会话 医学，通过在线资源加强该计划的传播，并通过网络增加联系- 基于方法。